Researchers at Baylor College of Medicine have developed a new compound called d16 that can reduce tumor growth and overcome therapeutic resistance in mutant p53-bearing cancers in the lab. The findings, published in the journal Cancer Research Communications , a journal of the American Association for Cancer Research , open opportunities for new combination therapies for these difficult-to-treat cancers. "One of the most common alterations in many human cancers is mutations in p53, a gene that normally provides one of the most powerful shields against tumor growth," said first author, Dr.

https://www.miragenews.com/compound-d16-hinders-tumor-growth-beats-1093184/

#miragenews